FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917498620> ?p ?o ?g. }

• W2917498620 endingPage "e393" @default.
• W2917498620 startingPage "e386" @default.
• W2917498620 abstract "Purpose This study aimed to determine the feasibility and maximally tolerated dose of hypofractionated, conformal radiation therapy (RT) in patients with liver metastases. Methods and materials Nonsurgical patients with ≤5 liver metastases (sum of maximal diameter of all lesions ≤8 cm) were included in the study. There were 4 dose levels: 35 Gy, 40 Gy (starting level), 45 Gy, and 50 Gy, in 10 fractions. The clinical target volume included metastases identified on contrast computed tomography or magnetic resonance imaging with a 5-mm margin within the liver. The planning target volume margin ranged from 4 to 30 mm, depending on breathing motion. Dose-limiting toxicities were defined as RT-related grade ≥4 hepatic or gastrointestinal toxicities or thrombocytopenia occurring within 90 days of the start of RT. Results A total of 26 patients with metastases from colorectal (8 patients), breast (7 patients) and other malignancies (11 patients) were enrolled between November 2005 and December 2010. Twenty-three patients were evaluable (8, 7, and 8 on the 40, 45, and 50 Gy dose levels, respectively). Two patients assigned to 50 Gy received 35 Gy owing to normal tissue limits, so 2 additional patients were treated to 50 Gy. There were no dose-limiting toxicities on any of the dose levels. On the 45 Gy dose level, 1 patient developed reversible grade 3 enteritis (37 days from RT start) and diarrhea (22 days); another patient developed grade 3 lymphopenia (23 days). At the 50 Gy dose level, 1 patient had grade 3 hyperglycemia (74 days), and another patient developed grade 3 lymphopenia (13 days), colonic hemorrhage (325 days), and colonic gastrointestinal obstruction (325 days). With a potential median follow-up of 66.1 months (range, 34.6-89.0 months), no other late toxicities were observed. Conclusions Treatment of liver metastases with 50 Gy in 10 fractions was feasible and safe in a multi-institutional setting." @default.
• W2917498620 created "2019-03-02" @default.
• W2917498620 creator A5016694714 @default.
• W2917498620 creator A5016976503 @default.
• W2917498620 creator A5017916544 @default.
• W2917498620 creator A5019086649 @default.
• W2917498620 creator A5023270374 @default.
• W2917498620 creator A5035857272 @default.
• W2917498620 creator A5037659354 @default.
• W2917498620 creator A5059663454 @default.
• W2917498620 creator A5062040958 @default.
• W2917498620 date "2019-07-01" @default.
• W2917498620 modified "2023-10-11" @default.
• W2917498620 title "NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases" @default.
• W2917498620 cites W1501842160 @default.
• W2917498620 cites W1509308704 @default.
• W2917498620 cites W1528207664 @default.
• W2917498620 cites W1891507428 @default.
• W2917498620 cites W1895794010 @default.
• W2917498620 cites W1967348067 @default.
• W2917498620 cites W1982200074 @default.
• W2917498620 cites W1994521878 @default.
• W2917498620 cites W1999020268 @default.
• W2917498620 cites W2010129875 @default.
• W2917498620 cites W2013754462 @default.
• W2917498620 cites W2024501410 @default.
• W2917498620 cites W2026511819 @default.
• W2917498620 cites W2027582694 @default.
• W2917498620 cites W2031688279 @default.
• W2917498620 cites W2090483604 @default.
• W2917498620 cites W2098599714 @default.
• W2917498620 cites W2100471896 @default.
• W2917498620 cites W2108463536 @default.
• W2917498620 cites W2113248775 @default.
• W2917498620 cites W2139248078 @default.
• W2917498620 cites W2139621327 @default.
• W2917498620 cites W2141517963 @default.
• W2917498620 cites W2166459387 @default.
• W2917498620 cites W2167561054 @default.
• W2917498620 cites W218054953 @default.
• W2917498620 cites W2536769127 @default.
• W2917498620 cites W2761351587 @default.
• W2917498620 cites W2897004478 @default.
• W2917498620 cites W4226151179 @default.
• W2917498620 cites W4231096603 @default.
• W2917498620 cites W4239112513 @default.
• W2917498620 cites W4376560538 @default.
• W2917498620 doi "https://doi.org/10.1016/j.prro.2019.02.013" @default.
• W2917498620 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6592755" @default.
• W2917498620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30825666" @default.
• W2917498620 hasPublicationYear "2019" @default.
• W2917498620 type Work @default.
• W2917498620 sameAs 2917498620 @default.
• W2917498620 citedByCount "10" @default.
• W2917498620 countsByYear W29174986202020 @default.
• W2917498620 countsByYear W29174986202021 @default.
• W2917498620 countsByYear W29174986202022 @default.
• W2917498620 countsByYear W29174986202023 @default.
• W2917498620 crossrefType "journal-article" @default.
• W2917498620 hasAuthorship W2917498620A5016694714 @default.
• W2917498620 hasAuthorship W2917498620A5016976503 @default.
• W2917498620 hasAuthorship W2917498620A5017916544 @default.
• W2917498620 hasAuthorship W2917498620A5019086649 @default.
• W2917498620 hasAuthorship W2917498620A5023270374 @default.
• W2917498620 hasAuthorship W2917498620A5035857272 @default.
• W2917498620 hasAuthorship W2917498620A5037659354 @default.
• W2917498620 hasAuthorship W2917498620A5059663454 @default.
• W2917498620 hasAuthorship W2917498620A5062040958 @default.
• W2917498620 hasBestOaLocation W29174986201 @default.
• W2917498620 hasConcept C126322002 @default.
• W2917498620 hasConcept C126838900 @default.
• W2917498620 hasConcept C143409427 @default.
• W2917498620 hasConcept C2989005 @default.
• W2917498620 hasConcept C509974204 @default.
• W2917498620 hasConcept C71924100 @default.
• W2917498620 hasConceptScore W2917498620C126322002 @default.
• W2917498620 hasConceptScore W2917498620C126838900 @default.
• W2917498620 hasConceptScore W2917498620C143409427 @default.
• W2917498620 hasConceptScore W2917498620C2989005 @default.
• W2917498620 hasConceptScore W2917498620C509974204 @default.
• W2917498620 hasConceptScore W2917498620C71924100 @default.
• W2917498620 hasFunder F4320337351 @default.
• W2917498620 hasIssue "4" @default.
• W2917498620 hasLocation W29174986201 @default.
• W2917498620 hasLocation W29174986202 @default.
• W2917498620 hasLocation W29174986203 @default.
• W2917498620 hasLocation W29174986204 @default.
• W2917498620 hasOpenAccess W2917498620 @default.
• W2917498620 hasPrimaryLocation W29174986201 @default.
• W2917498620 hasRelatedWork W1989985079 @default.
• W2917498620 hasRelatedWork W2049214470 @default.
• W2917498620 hasRelatedWork W2073690763 @default.
• W2917498620 hasRelatedWork W2113200719 @default.
• W2917498620 hasRelatedWork W2299437252 @default.
• W2917498620 hasRelatedWork W2384708512 @default.
• W2917498620 hasRelatedWork W2902148150 @default.
• W2917498620 hasRelatedWork W3032055452 @default.
• W2917498620 hasRelatedWork W3094186661 @default.

• next